Neuropathy Assessment and Treatment Patterns in Patients With Hereditary Transthyretin Amyloidosis: A Single-Center Analysis of Stabilizer and Gene Silencer Utilization

Background Hereditary transthyretin amyloidosis (hATTR) manifests as cardiomyopathy and/or polyneuropathy. The V142I variant predominantly causes cardiac disease in African Americans, though neurological involvement may be underrecognized. We characterized neuropathy documentation and treatment patterns in a predominantly V142I cohort.